5-hydroxytryptamine receptors in the human cardiovascular system.

[1]  R. Eglen.  5-HT4 Receptors in the Brain and Periphery , 2013, Biotechnology Intelligence Unit.

[2]  F. Ingegnoli,et al.  [Raynaud's phenomenon]. , 2011, Reumatismo.

[3]  M. Brüss,et al.  5-Hydroxytryptamine-induced contraction of human temporal arteries coexpressing 5-HT2A receptors and wild-type or variant (Phe124Cys) 5-HT1B receptors: increased contribution of 5-HT1B receptors to the total contractile amplitude in arteries from Phe124Cys heterozygous individuals , 2006, Pharmacogenetics and genomics.

[4]  D. Triggle.  L-type calcium channels. , 2006, Current pharmaceutical design.

[5]  F. Levy,et al.  Fading of 5‐HT4 receptor‐mediated inotropic responses to 5‐hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium , 2006, British journal of pharmacology.

[6]  K. Krobert,et al.  Activation of Adenylyl Cyclase by Endogenous Gs-Coupled Receptors in Human Embryonic Kidney 293 Cells Is Attenuated by 5-HT7 Receptor Expression , 2005, Molecular Pharmacology.

[7]  D. Richter,et al.  5-HT7 Receptor Is Coupled to Gα Subunits of Heterotrimeric G12-Protein to Regulate Gene Transcription and Neuronal Morphology , 2005, The Journal of Neuroscience.

[8]  K. Krobert,et al.  Dual Serotonergic Regulation of Ventricular Contractile Force Through 5-HT2A and 5-HT4 Receptors Induced in the Acute Failing Heart , 2005, Circulation research.

[9]  Frank Lezoualc'h,et al.  Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes. , 2005, Journal of molecular and cellular cardiology.

[10]  H. Bönisch,et al.  Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor , 2005, Neurochemistry International.

[11]  J. Buyon,et al.  Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. , 2005, Journal of autoimmunity.

[12]  K. Krobert,et al.  Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants , 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  K. Erol,et al.  5-Hydroxytryptamine-2A receptor gene (HTR 2 A) candidate polymorphism (T 102 C): Role for human platelet function under pharmacological challenge ex vivo. , 2005, Methods and findings in experimental and clinical pharmacology.

[14]  F. Lezoualc’h,et al.  Constitutive dimerization of human serotonin 5‐HT4 receptors in living cells , 2005, FEBS letters.

[15]  M. Gershon.  Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. , 2005, Journal of clinical gastroenterology.

[16]  J. Zgombick,et al.  [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties , 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  J. Launay,et al.  The Natural Mutation Encoding a C Terminus-Truncated 5-Hydroxytryptamine2B Receptor Is a Gain of Proliferative Functions , 2005, Molecular Pharmacology.

[18]  A. Workman,et al.  Electrophysiological Effects of Prucalopride, a Novel Enterokinetic Agent, on Isolated Atrial Myocytes from Patients Treated with β-Adrenoceptor Antagonists , 2005, Journal of Pharmacology and Experimental Therapeutics.

[19]  R. Groszmann,et al.  Portal hypertension: from bedside to bench. , 2005, Journal of clinical gastroenterology.

[20]  K. Park,et al.  The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans. , 2005, Journal of biochemistry and molecular biology.

[21]  R. Fossmark,et al.  Long-Term Serotonin Administration Induces Heart Valve Disease in Rats , 2005, Circulation.

[22]  K. Krobert,et al.  Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure. , 2005, Cardiovascular research.

[23]  A. Mugelli,et al.  Pharmacological modulation of the hyperpolarization-activated current (I f) in human atrial myocytes: focus on G protein-coupled receptors. , 2005, Journal of molecular and cellular cardiology.

[24]  G. Uhl,et al.  The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse. , 2004, Pharmacogenetics.

[25]  S. Cichon,et al.  Systematic screening for mutations in the human N-methyl-D-aspartate receptor 1 gene in schizophrenic patients from the German population. , 2004, Psychiatric genetics.

[26]  E. sanders-Bush,et al.  His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. , 2004, Molecular pharmacology.

[27]  A. Becker.  How structurally normal are human atria in patients with atrial fibrillation? , 2004, Heart rhythm.

[28]  R. Vickery,et al.  The 5‐HT4 receptor agonist, tegaserod, is a potent 5‐HT2B receptor antagonist in vitro and in vivo , 2004, British journal of pharmacology.

[29]  R. Kerwin,et al.  The –1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity , 2004, Biological Psychiatry.

[30]  F. Levy,et al.  Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  L. Monassier,et al.  Involvement of the Serotonin 5-HT2B Receptor in Cardiac Hypertrophy Linked to Sympathetic Stimulation: Control of Interleukin-6, Interleukin-1&bgr;, and Tumor Necrosis Factor-&agr; Cytokine Production by Ventricular Fibroblasts , 2004, Circulation.

[32]  Prashanthan Sanders,et al.  Changes in Atrial Fibrillation Cycle Length and Inducibility During Catheter Ablation and Their Relation to Outcome , 2004, Circulation.

[33]  Prashanthan Sanders,et al.  Pulmonary veins in the substrate for atrial fibrillation: the "venous wave" hypothesis. , 2004, Journal of the American College of Cardiology.

[34]  A. Lang,et al.  Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists , 2004, Movement disorders : official journal of the Movement Disorder Society.

[35]  M. Humbert,et al.  Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension , 2004, Circulation research.

[36]  R. Kaiser,et al.  Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. , 2004, Pharmacogenetics.

[37]  S. Hahn,et al.  Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of Migraine , 2004, Headache.

[38]  K. Krobert,et al.  Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i) , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[39]  L. Hunyady,et al.  Control of aldosterone secretion: a model for convergence in cellular signaling pathways. , 2004, Physiological reviews.

[40]  P. Sham,et al.  Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene. , 2004, Nucleic acids research.

[41]  F. Levy,et al.  Functional 5-HT receptors in human occipital artery , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  H. Bönisch,et al.  Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor. , 2004, Pharmacogenetics.

[43]  M. Brown,et al.  Triptans in migraine , 2004, Neurology.

[44]  U. Hacksell,et al.  Pharmacology of polymorphic variants of the human 5-HT1A receptor. , 2004, Biochemical pharmacology.

[45]  R. Hen,et al.  Attenuated Response to Stress and Novelty and Hypersensitivity to Seizures in 5-HT4 Receptor Knock-Out Mice , 2004, The Journal of Neuroscience.

[46]  M. Höltje,et al.  Serotonylation of Small GTPases Is a Signal Transduction Pathway that Triggers Platelet α-Granule Release , 2003, Cell.

[47]  A. Workman,et al.  Electrophysiological effects of 5‐hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic β‐adrenoceptor blockade , 2003, British journal of pharmacology.

[48]  F. Grimminger,et al.  The tantalizing triplet of pulmonary hypertension-BMP receptors, serotonin receptors, and angiopoietins. , 2003, Cardiovascular research.

[49]  M. Parmentier,et al.  Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. , 2003, Cardiovascular research.

[50]  J. Mallet,et al.  Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. Fadel,et al.  Polymorphism of the Serotonin Transporter Gene and Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease , 2003, Circulation.

[52]  B. Roth,et al.  Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization. , 2003, Biochemistry.

[53]  E. sanders-Bush,et al.  Serotonin 5-ht2 receptors: molecular and genomic diversity. , 2003, Molecular interventions.

[54]  T. Suzuki,et al.  Association of a haplotype in the serotonin 5‐HT4 receptor gene (HTR4) with Japanese schizophrenia , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[55]  M. Hamon,et al.  Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.

[56]  D. Atar,et al.  Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin , 2003, European journal of heart failure.

[57]  E. Kirkness,et al.  A cytoplasmic region determines single-channel conductance in 5-HT3 receptors , 2003, Nature.

[58]  S. Kimmel,et al.  Effect of Antidepressants and Their Relative Affinity for the Serotonin Transporter on the Risk of Myocardial Infarction , 2003, Circulation.

[59]  E. Schwartz,et al.  The combination of glycoprotein IIIa PlA polymorphism with polymorphism of serotonin transporter as an independent strong risk factor for the occurrence of coronary thrombosis. , 2003, Molecular genetics and metabolism.

[60]  N. Messaddeq,et al.  Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5‐HT2B‐receptor signaling , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  R. Kaiser,et al.  Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  V. Setola,et al.  3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. , 2003, Molecular pharmacology.

[63]  J. Kapeller,et al.  Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. , 2003, Gene.

[64]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[65]  J. Seward,et al.  Factors associated with progression of carcinoid heart disease. , 2003, The New England journal of medicine.

[66]  M. Wacker,et al.  Role of serotonin in thromboxane A2-induced coronary chemoreflex. , 2003, American journal of physiology. Heart and circulatory physiology.

[67]  Jiye Zhu,et al.  [Expression of 5-hydroxytamine receptors in hepatic stellate cell and action of 5-hydroxytamine on biological characteristics of hepatic stellate cell]. , 2003, Zhonghua wai ke za zhi [Chinese journal of surgery].

[68]  V. Álvarez,et al.  5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. , 2003, Clinical science.

[69]  O. Yildiz,et al.  Pharmacologic Characterization of Contractile Serotonergic Receptors in Human Isolated Mesenteric Artery , 2003, Journal of cardiovascular pharmacology.

[70]  H. Bönisch,et al.  Impairment of signal transduction in response to stimulation of the naturally occurring Pro279Leu variant of the h5-HT7(a) receptor. , 2003, Pharmacogenetics.

[71]  R. Fischmeister,et al.  5-HT4 receptor ligands: applications and new prospects. , 2003, Journal of medicinal chemistry.

[72]  S. Russmann,et al.  Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod , 2003, European Journal of Clinical Pharmacology.

[73]  J. Longhurst,et al.  Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5‐HT3 receptors , 2002, The Journal of physiology.

[74]  J. Duan,et al.  DNA variation and psychopharmacology of the human serotonin receptor 1B (HTR1B) gene. , 2002, Pharmacogenomics.

[75]  S. Sardi,et al.  Characterization of 5-HT receptor subtypes mediating contraction in human umbilical vein. 1. Evidence of involvement of 5-HT2A receptors using functional and radioligand binding assays , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[76]  F. Pelorosso,et al.  Characterization of 5-HT receptor subtypes mediating contraction in human umbilical vein. 2. Evidence of involvement of 5-HT1B receptors using functional studies , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[77]  F. Wigley.  Clinical practice. Raynaud's Phenomenon. , 2002, The New England journal of medicine.

[78]  M. Humbert,et al.  Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension , 2002, Nature Medicine.

[79]  F. Cambien,et al.  Serotonin Transporter Gene Polymorphism and Myocardial Infarction: Etude Cas-Témoins de l’Infarctus du Myocarde (ECTIM) , 2002, Circulation.

[80]  D. Richter,et al.  5-Hydroxytryptamine 4(a) Receptor Is Coupled to the Gα Subunit of Heterotrimeric G13 Protein* , 2002, The Journal of Biological Chemistry.

[81]  Hsiao-Fang Sunny Sun,et al.  Association study of novel human serotonin 5-HT1B polymorphisms with alcohol dependence in taiwanese han , 2002, Biological Psychiatry.

[82]  Daniel Hoyer,et al.  Molecular, pharmacological and functional diversity of 5-HT receptors , 2002, Pharmacology Biochemistry and Behavior.

[83]  M. Comer,et al.  Pharmacology of the Selective 5‐HT1B/1D Agonist Frovatriptan , 2002, Headache.

[84]  P. Saxena,et al.  Characterization of Sumatriptan-Induced Contractions in Human Isolated Blood Vessels Using Selective 5-HT1B and 5-HT1D Receptor Antagonists and In Situ Hybridization , 2002 .

[85]  J. Pickard,et al.  5-HT1B-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan. , 2002, British journal of clinical pharmacology.

[86]  K. Krobert,et al.  The human 5‐HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects , 2002, British journal of pharmacology.

[87]  H. Vaudry,et al.  Characterization of Serotonin4 Receptors in Adrenocortical Aldosterone-Producing Adenomas: In Vivo and in Vitro Studies , 2002 .

[88]  R. Lipton,et al.  Migraine--current understanding and treatment. , 2002, The New England journal of medicine.

[89]  S. Nattel.  New ideas about atrial fibrillation 50 years on , 2002, Nature.

[90]  M. Maclean,et al.  Contribution of the 5-HT1B Receptor to Hypoxia-Induced Pulmonary Hypertension: Converging Evidence Using 5-HT1B-Receptor Knockout Mice and the 5-HT1B/1D-Receptor Antagonist GR127935 , 2001, Circulation research.

[91]  B. Pollock,et al.  Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. , 2001, The American journal of psychiatry.

[92]  J. Raymond,et al.  Multiplicity of mechanisms of serotonin receptor signal transduction. , 2001, Pharmacology & therapeutics.

[93]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[94]  M. Ferrari,et al.  Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial , 2001, The Lancet.

[95]  H. Vaudry,et al.  Production and metabolism of serotonin (5-HT) by the human adrenal cortex: paracrine stimulation of aldosterone secretion by 5-HT. , 2001, The Journal of clinical endocrinology and metabolism.

[96]  J. Cortijo,et al.  Vascular Effects of the New Anti-Migraine Agent Almotriptan on Human Cranial and Peripheral Arteries , 2001, Cephalalgia : an international journal of headache.

[97]  S. Marshall,et al.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. , 2001, Rheumatology.

[98]  G. Guillon,et al.  Expression and regulation of adenylyl cyclase isoforms in the human adrenal gland. , 2001, The Journal of clinical endocrinology and metabolism.

[99]  S. Leal,et al.  Novel and previously reported single-nucleotide polymorphisms in the human 5-HT(1B) receptor gene: no association with cocaine or alcohol abuse or dependence. , 2001, American journal of medical genetics.

[100]  J. Block,et al.  Raynaud's phenomenon , 2001, The Lancet.

[101]  D. Middlemiss,et al.  Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. , 2001, Brain research. Molecular brain research.

[102]  K. Krobert,et al.  The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[103]  R Hen,et al.  Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. , 2001, European journal of pharmacology.

[104]  G. Hirose.  [Serotonin and migraine]. , 2001, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[105]  D. Levinson,et al.  Genetic diversity of the human serotonin receptor 1B (HTR1B) gene. , 2001, Genomics.

[106]  F. Lezoualc’h,et al.  Induction of neonatal lupus in pups of mice immunized with synthetic peptides derived from amino acid sequences of the serotoninergic 5‐HT4 receptor , 2001, European journal of immunology.

[107]  Trond Brattelid,et al.  5-HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[108]  E. Hamel,et al.  Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles , 2001, British journal of pharmacology.

[109]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[110]  T. Yoshida,et al.  Suppressive Effect of Sarpogrelate Hydrochloride on Respiratory Failure and Right Ventricular Failure with Pulmonary Hypertension in Patients with Systemic Sclerosis , 2000, The Journal of international medical research.

[111]  A. Bogers,et al.  Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. , 2000, European journal of pharmacology.

[112]  W. White,et al.  &bgr;2-Adrenergic and Several Other G Protein–Coupled Receptors in Human Atrial Membranes Activate Both Gs and Gi , 2000 .

[113]  H. Eichler,et al.  Paroxetine decreases platelet serotonin storage and platelet function in human beings , 2000, Clinical pharmacology and therapeutics.

[114]  H. Bönisch,et al.  Pharmacological properties of the naturally occurring Phe-124-Cys variant of the human 5-HT1B receptor: changes in ligand binding, G-protein coupling and second messenger formation. , 2000, Pharmacogenetics.

[115]  F. Lezoualc’h,et al.  Pharmacological characterization of the human 5‐HT4(d) receptor splice variant stably expressed in Chinese hamster ovary cells , 2000, British journal of pharmacology.

[116]  D. Isenberg,et al.  Anti‐SSA/Ro52 autoantibodies blocking the cardiac 5‐HT4 serotoninergic receptor could explain neonatal lupus congenital heart block , 2000, European journal of immunology.

[117]  G. Mcallister,et al.  Identification and characterization of a truncated variant of the 5-hydroxytryptamine2A receptor produced by alternative splicing , 2000, Brain Research.

[118]  A. Evans,et al.  Inhibition of sustained hypoxic vasoconstriction by Y‐27632 in isolated intrapulmonary arteries and perfused lung of the rat , 2000, British journal of pharmacology.

[119]  H. Odendaal,et al.  Serotonin Antagonism and Serotonin Antagonists in Pregnancy: Role of Ketanserin , 2000, Obstetrical & gynecological survey.

[120]  M. Maclean,et al.  5‐hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension , 2000, British journal of pharmacology.

[121]  A. Dierich,et al.  Serotonin 2B receptor is required for heart development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[122]  A. Becker,et al.  Left Atrial Myocardial Extension onto Pulmonary Veins in Humans: , 2000, Journal of cardiovascular electrophysiology.

[123]  S. Mace,et al.  Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression , 2000, Expert opinion on pharmacotherapy.

[124]  H. Pertz,et al.  Further evidence that 5‐HT‐induced relaxation of pig pulmonary artery is mediated by endothelial 5‐HT2B receptors , 2000, British journal of pharmacology.

[125]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[126]  W. Bax,et al.  Human isolated coronary artery contraction to sumatriptan characterised by the selective 5-HT1B/1D receptor antagonist GR55562. , 2000, Pharmacology & toxicology.

[127]  K. Hirata,et al.  T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. , 2000, Atherosclerosis.

[128]  D. Sakai,et al.  Ileal carcinoid tumor complicating carcinoid heart disease and secondary retroperitoneal fibrosis , 2000, Pathology international.

[129]  J. Schuurkes,et al.  An improved in vitro bioassay for the study of 5‐HT4 receptors in the human isolated large intestinal circular muscle , 2000, British journal of pharmacology.

[130]  Y. Wong,et al.  Preactivation permits subsequent stimulation of phospholipase C by G(i)-coupled receptors. , 2000, Molecular pharmacology.

[131]  R. Rothman,et al.  Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. , 2000, The American journal of cardiology.

[132]  Philippe Manivet,et al.  PDZ-dependent Activation of Nitric-oxide Synthases by the Serotonin 2B Receptor* , 2000, The Journal of Biological Chemistry.

[133]  J. Launay,et al.  5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[134]  B. Leventhal,et al.  Mutation screening of human 5-HT(2B)receptor gene in early-onset obsessive-compulsive disorder. , 2000, Molecular and cellular probes.

[135]  E. Hamel,et al.  No contractile effect for 5‐HT1D and 5‐HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery , 2000, British journal of pharmacology.

[136]  F. Lezoualc’h,et al.  Isolation of the serotoninergic 5‐HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6‐glial and CHO cell lines , 2000, British journal of pharmacology.

[137]  M. Jurzak,et al.  Structure of the Human Serotonin 5‐HT4 Receptor Gene and Cloning of a Novel 5‐HT4 Splice Variant , 2000, Journal of neurochemistry.

[138]  H. Vaudry,et al.  Effect of Serotonin4 (5-HT4) Receptor Agonists on Aldosterone Secretion in Idiopathic Hyperaldosteronism , 2000, Endocrine research.

[139]  S. Boyce,et al.  Possible Antimigraine Mechanisms of Action of the 5HT1F Receptor Agonist LY334370 , 1999, Cephalalgia : an international journal of headache.

[140]  R M Eglen,et al.  Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. , 1999, Circulation.

[141]  L. Edvinsson,et al.  Contractile 5‐HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry , 1999, British journal of pharmacology.

[142]  C. Glass,et al.  The Pharmacological and Functional Characteristics of the Serotonin 5-HT3A Receptor Are Specifically Modified by a 5-HT3B Receptor Subunit* , 1999, The Journal of Biological Chemistry.

[143]  M. Maclean,et al.  5‐hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5‐HT1B receptor , 1999, British journal of pharmacology.

[144]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[145]  J. Nordrehaug,et al.  Serotonin is associated with coronary artery disease and cardiac events. , 1999, Circulation.

[146]  J. Villemure,et al.  Multiple Microvascular and Astroglial 5-Hydroxytryptamine Receptor Subtypes in Human Brain: Molecular and Pharmacologic Characterization , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[147]  R. Hargreaves,et al.  Pathophysiology of Migraine — New Insights , 1999, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[148]  C. Triggle,et al.  Functional characterization and m‐RNA expression of 5‐HT receptors mediating contraction in human umbilical artery , 1999, British journal of pharmacology.

[149]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[150]  T. Arinami,et al.  A Synergistic Effect of Serotonin Transporter Gene Polymorphism and Smoking in Association with CHD , 1999, Thrombosis and Haemostasis.

[151]  T. Branchek,et al.  Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. , 1999, European journal of pharmacology.

[152]  J. Bockaert,et al.  Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.

[153]  H. Bönisch,et al.  Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. , 1999, Pharmacogenetics.

[154]  John A. Peters,et al.  The 5-HT3B subunit is a major determinant of serotonin-receptor function , 1999, Nature.

[155]  T. Gray,et al.  Monoamine- and histamine-synthesizing enzymes and neurotransmitters within neurons of adult human cardiac ganglia. , 1999, Circulation.

[156]  A. Fishman.  Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.

[157]  A. Workman,et al.  Serotonin, I(f) and human atrial arrhythmia. , 1998, Cardiovascular research.

[158]  H. Bönisch,et al.  Molecular cloning of alternatively spliced human 5-HT3 receptor cDNAs. , 1998, Annals of the New York Academy of Sciences.

[159]  J. Bockaert,et al.  5‐HT4 Receptors: Cloning and Expression of New Splice Variants , 1998, Annals of the New York Academy of Sciences.

[160]  M. Göthert,et al.  Genetic Variation in Human 5‐HT Receptors: Potential Pathogenetic and Pharmacological Role a , 1998, Annals of the New York Academy of Sciences.

[161]  A Mugelli,et al.  Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes. , 1998, Cardiovascular research.

[162]  J. Weil,et al.  Inactivation of GiαProteins Increases Arrhythmogenic Effects ofβ-Adrenergic Stimulation in the Heart , 1998 .

[163]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[164]  S. Garrigue,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[165]  A. Brown,et al.  5‐HT1B receptor‐mediated contractions in human temporal artery: evidence from selective antagonists and 5‐HT receptor mRNA expression , 1998, British journal of pharmacology.

[166]  A. A. Parsons,et al.  Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. , 1998, Journal of cardiovascular pharmacology.

[167]  M. J. Arranz,et al.  Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response , 1998, Schizophrenia Research.

[168]  M. Ferrari,et al.  Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.

[169]  H. Lenzi,et al.  Increased reactivity to 5-hydroxytryptamine of portal veins from mice infected with Schistosoma mansoni. , 1998, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[170]  L. Descarries,et al.  Endothelial expression of the 5-hydroxytryptamine1B antimigraine drug receptor in rat and human brain microvessels , 1998, Neuroscience.

[171]  R. Fischmeister,et al.  Cloning, Expression, and Pharmacology of Four Human 5‐Hydroxytryptamine4 Receptor Isoforms Produced by Alternative Splicing in the Carboxyl Terminus , 1998, Journal of neurochemistry.

[172]  A. Silman,et al.  Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. , 1998, The Cochrane database of systematic reviews.

[173]  R. Ophoff,et al.  5‐HT1B Receptor Polymorphism and Clinical Response to Sumatriptan , 1998, Headache.

[174]  S. Läer,et al.  Receptor mechanisms involved in the 5‐HT‐induced inotropic action in the rat isolated atrium , 1998, British journal of pharmacology.

[175]  Jeremy Veenstra-Vander Weele,et al.  Serotonin Transporter and Seasonal Variation in Blood Serotonin in Families with Obsessive-Compulsive Disorder , 1998, Neuropsychopharmacology.

[176]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[177]  J. Palacios,et al.  Characterization of 5‐HT receptors on human pulmonary artery and vein: functional and binding studies , 1997, British journal of pharmacology.

[178]  B. R. Hsu,et al.  Effect of Cisapride, a Serotonin‐4 Receptor Agonist, on Aldosterone Secretion: Absence of Age‐Related Change , 1997, Journal of clinical pharmacology.

[179]  J. Ottervanger,et al.  Characteristics and determinants of sumatriptan-associated chest pain. , 1997, Archives of neurology.

[180]  M. Jurzak,et al.  Cloning and Expression of a Human Serotonin 5‐HT4 Receptor cDNA , 1997, Journal of neurochemistry.

[181]  J. Bockaert,et al.  Cloning and expression of human 5‐HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase , 1997, Neuroreport.

[182]  R. Eglen,et al.  Cloning, expression and pharmacology of a truncated splice variant of the human 5‐HT7 receptor (h5‐HT7(b)) , 1997 .

[183]  M. J. Burton,et al.  SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[184]  R. Fischmeister,et al.  Molecular and functional characterization of a 5‐HT4 receptor cloned from human atrium , 1997, FEBS letters.

[185]  P. Priollet,et al.  Physiopathologie du phénomène de Raynaud : données actuelles , 1997 .

[186]  H. Manji,et al.  A Naturally Occurring Amino Acid Substitution of the Human Serotonin 5‐HT2A Receptor Influences Amplitude and Timing of Intracellular Calcium Mobilization , 1997, Journal of neurochemistry.

[187]  M. Nöthen,et al.  Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia , 1997, The Lancet.

[188]  D. Middlemiss,et al.  Importance of h5-HT1B Receptor Selectivity for 5-HT Terminal Autoreceptor Activity: an In Vivo Microdialysis Study in the Freely-moving Guinea-pig , 1997, Neuropharmacology.

[189]  R. Kohen,et al.  Four 5‐Hydroxytryptamine7 (5‐HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron‐Exon Organization , 1997, Journal of neurochemistry.

[190]  M. Boutjdir,et al.  Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. , 1997, Circulation research.

[191]  P. Ridker,et al.  PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis , 1997, The Lancet.

[192]  M. Stjernquist,et al.  5-Hydroxytryptamine contracts human uterine artery smooth muscle predominantly via 5-HT2 receptors. , 1997, Human reproduction.

[193]  K. Hirata,et al.  Disparity between serotonin‐ and acetylcholine‐provoked coronary artery Spasm , 1997, Clinical cardiology.

[194]  J. Mellembakken,et al.  Characterization of the vasodilatatory response to serotonin in human umbilical arteries perfused in vitro. The influence of the endothelium. , 1997, Early human development.

[195]  U. Pesonen,et al.  Two naturally occurring amino acid substitutions of the 5-HT2A receptor: Similar prevalence in patients with seasonal affective disorder and controls , 1996, Biological Psychiatry.

[196]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[197]  M. Ferrari,et al.  Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane , 1996, British journal of pharmacology.

[198]  I. Ay,et al.  Hypertension increases the contractions to sumatriptan in the human internal mammary artery. , 1996, The Annals of thoracic surgery.

[199]  M. Rietschel,et al.  The human serotonin 7 (5-HT7) receptor gene: genomic organization and systematic mutation screening in schizophrenia and bipolar affective disorder. , 1996, Molecular psychiatry.

[200]  D. Collier,et al.  Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine , 1996, Neuroscience Letters.

[201]  M. Maclean,et al.  Evidence for 5‐HT1‐like receptor‐mediated vasoconstriction in human pulmonary artery , 1996, British journal of pharmacology.

[202]  I. Ay,et al.  5-HT1-like receptor-mediated contraction in the human internal mammary artery. , 1996, Journal of cardiovascular pharmacology.

[203]  H. Diener,et al.  Sumatriptan: Vasoactive Effect on Human Dural Vessels, Demonstrated by Subselective Angiography , 1996, Cephalalgia : an international journal of headache.

[204]  M. Rietschel,et al.  Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia , 1996, Human Genetics.

[205]  L. Sanders,et al.  Chronic β1-adrenoceptor blockade sensitises the H1 and H2 receptor systems in human atrium: role of cyclic nucleotides , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[206]  P. Randall,et al.  Improved Models for Pharmacological Null Experiments: Calculation of Drug Efficacy at Recombinant D1A Dopamine Receptors Stably Expressed in Clonal Cell Lines , 1996, Neuropharmacology.

[207]  J. Weiss,et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. , 1996, The New England journal of medicine.

[208]  J. Lynham,et al.  Comparison of the densities of 5-HT4 receptors, β1- and β2-adrenoceptors in human atrium: functional implications , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[209]  G. Martin,et al.  Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. , 1996, Trends in pharmacological sciences.

[210]  G. Gabbiani,et al.  Functional, endogenously expressed 5‐hydroxytryptamine 5‐ht7 receptors in human vascular smooth muscle cells , 1996, British journal of pharmacology.

[211]  H. Boddeke,et al.  5‐HT2B receptor‐mediated calcium release from ryanodine‐sensitive intracellular stores in human pulmonary artery endothelial cells , 1996, British journal of pharmacology.

[212]  H. Vaudry,et al.  Activation of 5-hydroxytryptamine4 receptors causes calcium influx in adrenocortical cells: involvement of calcium in 5-hydroxytryptamine-induced steroid secretion. , 1996, Molecular pharmacology.

[213]  A. Kaumann,et al.  Participation of 5‐HT1‐like and 5‐HT2A receptors in the contraction of human temporal artery by 5‐hydroxytryptamine and related drugs , 1996, British journal of pharmacology.

[214]  T. Blackburn,et al.  Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. , 1995, Molecular pharmacology.

[215]  S. Harding,et al.  Sensitization of Human Atrial 5-HT4 Receptors by Chronic β-Blocker Treatment , 1995 .

[216]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[217]  S. Mochizuki,et al.  Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. , 1995, Molecular pharmacology.

[218]  H. Lübbert,et al.  Expression of serotonin receptor mRNAs in blood vessels , 1995, FEBS letters.

[219]  J M Feldman,et al.  Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. , 1995, Circulation.

[220]  R. Eglen,et al.  The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors , 1995, British journal of pharmacology.

[221]  H. Kao,et al.  The 5‐HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. , 1995, The EMBO journal.

[222]  R. Beroukhim,et al.  Ultrastructure of the 5‐Hydroxytryptamine3 Receptor , 1995, Journal of neurochemistry.

[223]  B. Albat,et al.  Calcium Currents in Diseased Human Cardiac Cells , 1995, Journal of cardiovascular pharmacology.

[224]  M. Nöthen,et al.  Identification of Genetic Variation in the Human Serotonin 1Dβ Receptor Gene , 1994 .

[225]  E. Topol,et al.  Cell adhesion molecules in coronary artery disease. , 1994, Journal of the American College of Cardiology.

[226]  A. Kaumann.  Do human atrial 5-HT4 receptors mediate arrhythmias? , 1994, Trends in pharmacological sciences.

[227]  R. Groszmann.  Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences , 1994, Hepatology.

[228]  R. Moreau,et al.  Blood and plasma 5‐hydroxytryptamine levels in patients with cirrhosis , 1994, Hepatology.

[229]  H. Posival,et al.  Variable Participation of 5‐HT1‐Like Receptors and 5‐HT2 Receptors in Serotonin‐Induced Contraction of Human Isolated Coronary Arteries: 5‐HT1‐Like Receptors Resemble Cloned 5‐HT1Dβ Receptors , 1994, Circulation.

[230]  J. Olesen,et al.  5-Hydroxytryptamine mechanisms in primary headaches , 1994 .

[231]  M. Chandra,et al.  Serotonergic mechanisms in heart failure. , 1994, Indian heart journal.

[232]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[233]  L. Sanders,et al.  5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade , 1994, Naunyn-Schmiedeberg’s Archives of Pharmacology.

[234]  R. Cohen,et al.  Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon. , 1994, Clinical science.

[235]  M. Condorelli,et al.  Local effect of serotonin released during coronary angioplasty. , 1994, The New England journal of medicine.

[236]  A. Brown,et al.  Human arterial constrictor serotonin receptors. , 1993, Cardiovascular research.

[237]  H. Vaudry,et al.  Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studies. , 1993, The Journal of clinical endocrinology and metabolism.

[238]  T. Branchek,et al.  Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. , 1993, The Journal of biological chemistry.

[239]  L. Sanders,et al.  Both β1- and β2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[240]  J. Rupp,et al.  L-type calcium channel activity in human atrial myocytes as influenced by 5-HT , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[241]  W. Hillis,et al.  Sumatriptan and chest pain , 1993, The Lancet.

[242]  J. Angus,et al.  Comparison of contractile responses to 5‐hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2‐receptor agonist, U46619 , 1993, British journal of pharmacology.

[243]  J. Villemure,et al.  Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries. , 1993, Molecular pharmacology.

[244]  P. Pizcueta,et al.  Effects of ritanserin, a selective and specific S2‐serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long‐term bile duct ligation , 1993, Hepatology.

[245]  S. Friedman.  The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies , 1993 .

[246]  J. Ottervanger,et al.  Transmural myocardial infarction with sumatriptan , 1993, The Lancet.

[247]  M. Yacoub,et al.  Interaction Between Thromboxane A2 and 5‐Hydroxytryptamine Receptor Subtpes in Human Coronary Arteries , 1993, Circulation.

[248]  E. Grant.  Oral contraceptives off prescription , 1993, The Lancet.

[249]  M. Tansey,et al.  Sumatriptan in the acute treatment of migraine , 1993, Journal of the Neurological Sciences.

[250]  J. Kaufman,et al.  Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. , 1993, The American journal of cardiology.

[251]  W. Bax,et al.  5-Hydroxytryptamine stimulates human isolated atrium but not ventricle. , 1993, European journal of pharmacology.

[252]  J. Lorrain,et al.  5-HT4 receptors, present in piglet atria and sensitive to SDZ 205-557, are absent in papillary muscle. , 1992, European journal of pharmacology.

[253]  P. Saxena,et al.  5-Hydroxytryptamine-induced increase in left ventricular dP/dtmax does not suggest the presence of ventricular 5-HT4 receptors in the pig , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[254]  W. Hillis,et al.  The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. , 1992, British journal of clinical pharmacology.

[255]  A. Creutzig.  [Ergotamine-induced heart valve fibrosis and coronary microangiopathy?]. , 1992, Deutsche medizinische Wochenschrift.

[256]  W. Bax,et al.  5-Hydroxytryptamine increases contractile force in porcine right atrium but not in left ventricle , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[257]  J. Rupp,et al.  Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[258]  T. Cocks,et al.  5‐Hydroxytryptamine (5‐HT) mediates potent relaxation in the sheep isolated pulmonary vein via activation of 5‐HT4 receptors , 1992, British journal of pharmacology.

[259]  C. Dessy,et al.  A comparison of the potency of selective L-calcium channel blockers in human coronary and internal mammary arteries exposed to serotonin. , 1992, The Journal of pharmacology and experimental therapeutics.

[260]  R. Groszmann,et al.  Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. , 1992, The American journal of physiology.

[261]  W. Inman,et al.  Cardiorespiratory distress after sumatriptan given by injection. , 1992, BMJ.

[262]  M. Bodelsson,et al.  Heterogeneity of contractile 5-HT receptors in human hand veins. , 1992, European journal of pharmacology.

[263]  P. Romagnoli,et al.  Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. , 1992, Gastroenterology.

[264]  A. Maseri,et al.  Effect of Ketanserin on Proximal and Distal Coronary Constrictor Responses to Intracoronary Infusion of Serotonin in Patients With Stable Angina, Patients With Variant Angina, and Control Patients , 1992, Circulation.

[265]  P. Gupta,et al.  An endothelial 5‐HT receptor that mediates relaxation in guinea‐pig isolated jugular vein resembles the 5‐HT1D subtype , 1992, British journal of pharmacology.

[266]  N. Tsapatsaris,et al.  Increased prevalence of migraine and chest pain in patients with primary Raynaud disease. , 1992, Annals of internal medicine.

[267]  G. Dekker,et al.  Pathogenesis of preeclampsia: a hypothesis. , 1992, Clinical obstetrics and gynecology.

[268]  G. Gebhart,et al.  A critical review of the afferent pathways and the potential chemical mediators involved in cardiac pain , 1992, Neuroscience.

[269]  N. Curzen,et al.  Coronary vasospasm induced by subcutaneous sumatriptan. , 1992, BMJ.

[270]  L. Sanders,et al.  A 5-HT4-like receptor in human left atrium , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[271]  M. Feuilloley,et al.  Serotonin-induced stimulation of cortisol secretion from human adrenocortical tissue is mediated through activation of a serotonin4 receptor subtype , 1992, Neuroscience.

[272]  J. Bockaert,et al.  Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. , 1992, Molecular pharmacology.

[273]  F. Nevens,et al.  Effects of ritanserin, a selective and specific S2‐serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats , 1991, Hepatology.

[274]  G. Jacob,et al.  Cardiovascular responses to serotonin in experimental liver disease , 1991, Hepatology.

[275]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[276]  T. Verbeuren,et al.  5-Hydroxytryptamine-induced vasodilatation in the isolated perfused rat kidney: are endothelial 5-HT1A receptors involved? , 1991, European journal of pharmacology.

[277]  Morris J. Brown,et al.  A 5-HT4-like receptor in human right atrium , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[278]  J. Olesen,et al.  Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan , 1991, The Lancet.

[279]  M. Condorelli,et al.  Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. , 1991, The New England journal of medicine.

[280]  A. Maseri,et al.  Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. , 1991, The New England journal of medicine.

[281]  A. Kaumann.  Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptors , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

[282]  G. Martin,et al.  5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. , 1990, Cardiovascular research.

[283]  J. Caen,et al.  Platelet Aggregation Is Not Necessary for Occurrence of Raynaud's Phenomenon: A Clinical History and Laboratory Results , 1990, Angiology.

[284]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[285]  E. Whalley,et al.  Serotonin and Migraine , 1990, Annals of the New York Academy of Sciences.

[286]  N. Mcintyre,et al.  The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. , 1990, Journal of hepatology.

[287]  L. Sanders,et al.  A 5‐hydroxytryptamine receptor in human atrium , 1990, British journal of pharmacology.

[288]  D G Grahame-Smith,et al.  Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378. , 1990, European journal of pharmacology.

[289]  E. Ongini,et al.  Role of 5-HT2 receptors in serotonin-induced contraction in the human mammary artery. , 1990, European journal of pharmacology.

[290]  D. Brutsaert,et al.  Endocardium modulates myocardial inotropic response to 5-hydroxytryptamine. , 1989, The American journal of physiology.

[291]  M. Biondi,et al.  Abnormal platelet aggregation in patients with Raynaud's phenomenon. , 1989, Journal of clinical pathology.

[292]  J. McGrath,et al.  5‐HT1‐like receptors requiring functional cyclo‐oxygenase and 5‐HT2 receptors independent of cyclo‐oxygenase mediate contraction of the human umbilical artery , 1989, British journal of pharmacology.

[293]  M. Brown,et al.  A comparison of the effects of adrenaline and noradrenaline on human heart: the role of beta 1- and beta 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. , 1989, European heart journal.

[294]  R. Aster,et al.  The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. , 1989, The Journal of clinical investigation.

[295]  W. Feniuk,et al.  5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. , 1989, European journal of pharmacology.

[296]  P. Huet,et al.  Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension , 1989, Hepatology.

[297]  A. A. Parsons,et al.  5‐HT1‐like receptors mediate 5‐hydroxytryptamine‐induced contraction of human isolated basilar artery , 1989, British journal of pharmacology.

[298]  R. Groszmann,et al.  Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients , 1989, Hepatology.

[299]  R. Moreau,et al.  Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: Search for an additive effect , 1989, Hepatology.

[300]  R. Groszmann,et al.  ICI 169,369 selectively blocks 5-hydroxytryptamine2 receptors and lowers portal pressure in portal hypertensive rats. , 1988, Gastroenterology.

[301]  G. Blauw,et al.  5HT3 receptor‐mediated vasodilation in the human forearm , 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[302]  W. Schmitz,et al.  INCREASE IN MYOCARDIAL Gi-PROTEINS IN HEART FAILURE , 1988, The Lancet.

[303]  R. Groszmann,et al.  Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive rats , 1988, Hepatology.

[304]  W. Baumgartner,et al.  Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. , 1988, The Journal of clinical investigation.

[305]  A. Agostoni,et al.  Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. , 1988, International journal of cardiology.

[306]  A. Breckenridge,et al.  Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. , 1988, Hypertension.

[307]  K. Öberg,et al.  Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. , 1988, Circulation.

[308]  D. Cohen,et al.  Steady-state model for plasma free and platelet serotonin in man. , 1987, Life sciences.

[309]  M. Mulvany,et al.  Mechanical, morphological and pharmacological properties of oesophageal varices and small mesenteric veins in portal hypertensive rabbits. , 1987, Acta physiologica Scandinavica.

[310]  R. Moreau,et al.  Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: Possible role of serotonergic mechanisms in portal hypertension , 1987, Hepatology.

[311]  A. Bom,et al.  Reflex inhibition of efferent renal sympathetic nerve activity by 5-hydroxytryptamine and nicotine is elicited by different epicardial receptors , 1987, Pflügers Archiv.

[312]  R. Frye,et al.  Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. , 1987, Journal of the American College of Cardiology.

[313]  R. Groszmann,et al.  Hypersensitivity of mesenteric veins to 5‐hydroxytryptamine‐ and ketanserin‐induced reduction of portal pressure in portal hypertensive rats , 1986, British journal of pharmacology.

[314]  J. Docherty,et al.  An examination of 5‐hydroxytryptamine receptors in human saphenous vein , 1986, British journal of pharmacology.

[315]  J. Seibold,et al.  Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon. , 1986, The Journal of rheumatology.

[316]  Van Nueten Jm,et al.  Augmentation of vasoconstrictor responses to serotonin by acute and chronic factors: inhibition by ketanserin. , 1986 .

[317]  M. Gross,et al.  Central serotonergic stimulation of aldosterone secretion. , 1985, The Journal of clinical investigation.

[318]  J. Leysen,et al.  Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. , 1985, Journal of Biological Chemistry.

[319]  J. Leysen,et al.  Evidence for functional 5-HT2 receptor sites on human blood platelets. , 1984, Biochemical pharmacology.

[320]  S. Chierchia,et al.  Ergonovine-induced myocardial ischemia: no role for serotonergic receptors? , 1984, Circulation.

[321]  J. Fozard.  MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors , 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

[322]  Clara Carpeggiani,et al.  A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Evidence against a role for serotonin in the genesis of coronary vasospasm. , 1984, Circulation.

[323]  S. Ball,et al.  Mechanism of antihypertensive action of ketanserin in man. , 1983, British medical journal.

[324]  J. Frölich,et al.  Mechanism of antihypertensive action of ketanserin in man. , 1983 .

[325]  M. Briley,et al.  Reduced uptake of serotonin but unchanged 3H-imipramine binding in the platelets from cirrhotic patients. , 1981, Life sciences.

[326]  J. V. van Beek,et al.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. , 1981, The Journal of pharmacology and experimental therapeutics.

[327]  D. Waters,et al.  Is variant angina the coronary manifestation of a generalized vasospastic disorder? , 1981, The New England journal of medicine.

[328]  M. Sole,et al.  Serotonin Metabolism in the Normal and Failing Hamster Heart , 1979, Circulation research.

[329]  F. Pérez-Gómez,et al.  Prinzmetal's angina:reflex cardiovascular response during episode of pain. , 1979, British heart journal.

[330]  K. Nishi,et al.  Activation of afferent cardiac sympathetic nerve fibers of the cat by pain producing substances and by noxious heat , 1977, Pflügers Archiv.

[331]  F. Pérez-Gómez,et al.  Origin of ventricular reflexes caused by coronary arteriography. , 1977, British heart journal.

[332]  W. Roberts,et al.  The carcinoid endocardial plaque; an ultrastructural study. , 1976, Human pathology.

[333]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[334]  F. Abboud,et al.  Mechanisms mediating bradycardia during coronary arteriography. , 1974, The Journal of clinical investigation.

[335]  Y. Uchida,et al.  Excitation of afferent cardiac sympathetic nerve fibers during coronary occlusion. , 1974, The American journal of physiology.

[336]  E. Keat,et al.  Carcinoid Heart Disease , 1974, Proceedings of the Royal Society of Medicine.

[337]  E. Phillips,et al.  The pharmacology of human isolated pulmonary vascular tissue. , 1973, British journal of pharmacology.

[338]  R. Groszmann,et al.  Circulation times in the splanchnic and hepatic beds in alcoholic liver disease. , 1972, Gastroenterology.

[339]  C. Reich,et al.  Effects of vasoactive agents on isolated human umbilical arteries and veins. , 1972, The American journal of physiology.

[340]  W. Ziegler,et al.  Stimulation of aldosterone biosynthesis in vitro by serotonin. , 1968, Acta endocrinologica.

[341]  M. Greenberg.  Structure-activity relationship of tryptamine analogues on the heart of Venus mercenaria. , 1960, British journal of pharmacology and chemotherapy.

[342]  M. Greenberg.  The responses of the Venus heart to catechol amines and high concentration of 5-hydroxytryptamine. , 1960, British journal of pharmacology and chemotherapy.

[343]  A. Cournand,et al.  Some Circulatory Effects of 5‐Hydroxytryptamine in Man , 1960, Circulation.

[344]  S. Skinner,et al.  The stimulation of respiration by 5‐hydroxytryptamine in man , 1960, The Journal of physiology.

[345]  R. F. Whelan,et al.  Cardiovascular effects of intravenous infusions of 5-hydroxytryptamine in man. , 1959, British journal of pharmacology and chemotherapy.

[346]  J. Black,et al.  The effect of precursors of 5‐hydroxytryptamine on gastric secretion in anaesthetized dogs , 1959, The Journal of physiology.

[347]  W. Hollander,et al.  Serotonin and Antiserotonins: I. Their Circulatory, Respiratory, and Renal Effects in Man , 1957, Circulation.

[348]  Carcinoid Tumours , 1956 .

[349]  R. Worrall.  Reflex Inhibition , 1934 .

[350]  J. Adotey.  Ileal carcinoid. , 2006, Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria.

[351]  K. Krobert,et al.  Rationale for treatment of heart failure by blockade of ventricular serotonin receptors appearing in heart failure , 2005 .

[352]  M. Simoons,et al.  5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5-HT2 and 5-HT1D-like receptors, and a comparison with grafted veins , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[353]  S. Garattini,et al.  Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given d- and dl-fenfluramine for 15 days , 2004, European Journal of Clinical Pharmacology.

[354]  D. N. Bateman,et al.  The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam , 2004, European Journal of Clinical Pharmacology.

[355]  N. Freimer,et al.  Re‐Screening serotonin receptors for genetic variants identifies population and molecular genetic complexity , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[356]  E. Singer,et al.  B-HT 920 and B-HT 958: Presynaptic effects on electrically evoked 3H-dopamine release from slices of rat nucleus accumbens , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[357]  P. Cosnay,et al.  Polyclonal antibody effects on the human cardiac 5-HT4(e) receptors depend upon the expression system. , 2004, Receptors & channels.

[358]  D. Levinson,et al.  Polymorphisms in the 5′-untranslated region of the human serotonin receptor 1B (HTR1B) gene affect gene expression , 2003, Molecular Psychiatry.

[359]  K. Krobert,et al.  Unaltered agonist potency upon inducible 5-HT7(a) but not 5-HT4(b) receptor expression indicates agonist-independent association of 5-HT7(a) receptor and Gs. , 2003, Receptors & channels.

[360]  C. Iwai,et al.  Serotonin-2A receptor gene polymorphisms are associated with serotonin-induced platelet aggregation. , 2003, Thrombosis research.

[361]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[362]  M. Jurzak,et al.  Differences in Signal Transduction of Two 5-HT4Receptor Splice Variants: Compound Specificity and Dual Coupling with Gαs- and Gαi/o-Proteins , 2002 .

[363]  F. Lezoualc’h,et al.  Agonist-like activity of antibodies directed against the second extracellular loop of the human cardiac serotonin 5-HT4(e) receptor in transfected COS-7 cells. , 2002, Receptors & channels.

[364]  E. Hattori,et al.  Association between serotonin 4 receptor gene polymorphisms and bipolar disorder in Japanese case-control samples and the NIMH Genetics Initiative Bipolar Pedigrees , 2002, Molecular Psychiatry.

[365]  A. Berezin,et al.  [Relationship between myocardial remodeling and neurohumoral activation in patients with cardiac failure]. , 2001, Klinicheskaia meditsina.

[366]  B. Largent,et al.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.

[367]  A. Kaumann.  Gs protein-coupled receptors in human heart , 2000 .

[368]  J. Pickard,et al.  Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. , 1999, British journal of clinical pharmacology.

[369]  K. Hirata,et al.  Identification of mRNA for 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries. , 1999, Cardiovascular research.

[370]  R. Mayer,et al.  Medical progress : Carcinoid tumors , 1999 .

[371]  E. Lander,et al.  Characterization of single-nucleotide polymorphisms in coding regions of human genes , 1999, Nature Genetics.

[372]  K. Hirata,et al.  5-HT1Dbeta receptor mediates the supersensitivity of isolated coronary artery to serotonin in variant angina. , 1998, Chest.

[373]  L. Sanders,et al.  5-Hydroxytryptamine and Human Heart Function: The Role of 5-HT4 Receptors , 1998 .

[374]  M. Owen,et al.  A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter , 1998, Molecular Psychiatry.

[375]  Á. N. Chonchubhair.  Selective serotonin reuptake inhibitors. , 1998, Anaesthesia.

[376]  R. Eglen,et al.  Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). , 1997, British journal of pharmacology.

[377]  S. D. Lee,et al.  The hemodynamic effects of AT-112, an analog of ketanserin, in portal hypertensive rats. , 1997, Pharmacology.

[378]  M. Nöthen,et al.  Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. , 1997, Lancet.

[379]  B. Corya,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[380]  M. Bodelsson,et al.  Characteristics of contractile 5-HT receptors in isolated human omental arteries: presence of 5-HT1 and 5-HT2 receptors. , 1996, Pharmacology & toxicology.

[381]  M. Steinfath,et al.  Effects of metoprolol on myocardial β-adrenoceptors and Giα-proteins in patients with congestive heart failure , 1996, European Journal of Clinical Pharmacology.

[382]  D. Sommers,et al.  Effects of metoclopramide and tropisetron on aldosterone secretion possibly due to agonism and antagonism at the 5-HT4 receptor , 1996, European Journal of Clinical Pharmacology.

[383]  J. Raymond,et al.  Immunohistochemical mapping of cellular and subcellular distribution of 5-HT1A receptors in rat and human kidneys. , 1993, The American journal of physiology.

[384]  T. Branchek,et al.  A subfamily of 5-HT1D receptor genes. , 1992, Trends in pharmacological sciences.

[385]  R. Smith,et al.  The safety and tolerability of sumatriptan: an overview. , 1991, European neurology.

[386]  A. Kaumann.  5-HT4-like receptors in mammalian atria. , 1991, Journal of neural transmission. Supplementum.

[387]  T. Macedo,et al.  Pharmacological characterization of the postsynaptic serotonergic receptor in the human uterine artery. , 1991, Pharmacology.

[388]  Morris J. Brown,et al.  Heart 5-HT Receptors. A Novel 5-HT Receptor in Human Atrium , 1990 .

[389]  A. Brown,et al.  Allosteric modulation of arterial 5-HT2 receptors , 1990 .

[390]  P. Saxena,et al.  Cardiovascular Pharmacology of 5-Hydroxytryptamine , 1990 .

[391]  M. Semret,et al.  Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. , 1990, Gastroenterology.

[392]  C. Benedict,et al.  Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. , 1989, Circulation.

[393]  T. Cheng.  Platelet activation. , 1989, The Canadian journal of cardiology.

[394]  W. Janssens,et al.  Interaction between S2-serotonergic and alpha 1-adrenergic receptor activities at vascular sites. , 1988, Journal of cardiovascular pharmacology.

[395]  S. Ball,et al.  Mechanism of action of ketanserin in hypertension , 1986 .

[396]  W. Janssens,et al.  Augmentation of vasoconstrictor responses to serotonin by acute and chronic factors: inhibition by ketanserin. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.